Was Allergan’s Patent-Housing Agreement In Exchange For Sovereign Immunity a “Sham to Subvert the Existing Intellectual Property System?”

Allergan plc (“Allergan”) holds several patents for its prescription dry-eye medication Restasis. In 2015, Allergan sued Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., and Akorn Inc., (the “Generic Manufacturers”), for patent infringement following their filings of abbreviated new drug applications … Continue reading